Semaglutide: What the Clinical Evidence Shows About This GLP-1 Agonist

What it is

After a meal, your gut releases GLP-1, a hormone that slows the stomach, tells the brain you are full, and tells the pancreas to release insulin when blood sugar is high. It lasts about two minutes. Semaglutide is that hormone with two changes: a swapped amino acid that blocks the enzyme that destroys it, and a fatty chain that lets it ride on albumin, a blood protein. The result lasts about a week.

Novo Nordisk sells it three ways. Ozempic is the weekly injection for type 2 diabetes. Wegovy is the same molecule at a higher dose, approved for weight loss. Rybelsus is a daily pill for diabetes that works only because it is packaged with an absorption enhancer, and even then most of it does not get through.

Among the peptides on this site, semaglutide has the most evidence by a wide margin. The claims below come from trials with thousands of people in each.

What it is studied for

Weight loss and type 2 diabetes, both approved. Heart attack and stroke prevention in overweight people with heart disease, approved in 2024 on the strength of the SELECT trial. Kidney disease, fatty liver, and sleep apnea are in later trials.

What the evidence actually shows

Weight loss

STEP 1 enrolled 1,961 adults with obesity and no diabetes. After 68 weeks on 2.4 mg a week, plus diet and exercise advice, the semaglutide group had lost 14.9% of their body weight; the placebo group, 2.4%. About a third of the semaglutide group lost more than 20% (Wilding et al., 2021). Later STEP trials found less in people with diabetes (about 10%) and more when combined with intensive lifestyle programs (about 16%).

Diabetes

The SUSTAIN program showed HbA1c, the three-month blood-sugar average, falling by roughly 1.5 to 1.8 points, with weight loss on top. SUSTAIN-6, in 3,297 people with diabetes and high heart risk, found fewer heart attacks and strokes over two years, though it also saw more diabetic eye complications in people whose blood sugar dropped fast (Marso et al., 2016).

Heart protection

SELECT followed 17,604 overweight adults with existing heart disease and no diabetes for over three years. Semaglutide cut the combined rate of heart attack, stroke, and cardiovascular death by 20%. It was the first weight-loss drug to show that (Lincoff et al., 2023).

What happens when you stop

In the STEP 1 extension, people who stopped semaglutide regained about two-thirds of the lost weight within a year. Obesity, on this evidence, behaves like blood pressure: the drug manages it while you take it.

Muscle

Of the weight lost in the trials, roughly 25 to 40% was lean mass, which includes muscle. Whether lifting and eating enough protein fully prevents that is being studied. It matters most for older adults.

How it works

Semaglutide binds the GLP-1 receptor in the pancreas, the gut, and the brain. In the pancreas it boosts insulin only when blood sugar is high, which is why it rarely causes low blood sugar on its own, and it turns down glucagon. In the gut it slows emptying. In the brain it dampens hunger and, people say, the constant background noise of food thoughts. A meal study found people on semaglutide ate about a quarter fewer calories without trying (Blundell et al., 2017). The heart benefit is probably a mix of weight loss, lower blood pressure and inflammation, and direct effects on blood vessels; nobody has fully untangled it.

How it is used

Wegovy starts at 0.25 mg a week and steps up every four weeks through 0.5, 1, and 1.7 mg to 2.4 mg. The slow climb exists to keep nausea manageable; people who rush it feel worse. Ozempic runs 0.5 to 2 mg weekly. Injections go under the skin of the belly, thigh, or upper arm, same day each week, with or without food. Pens are kept refrigerated before first use.

Side effects and unknowns

Nausea, vomiting, diarrhea, and constipation are the common ones, worst during dose increases and usually fading. Some people never adjust and stop.

The rare, serious ones: pancreatitis; gallbladder attacks, which come with any fast weight loss; a boxed warning about thyroid C-cell tumors, from rat studies and never confirmed in people, but enough that anyone with a personal or family history of medullary thyroid cancer should not take it; and, in people with diabetes, a temporary worsening of eye disease when blood sugar falls quickly. Stomach paralysis and bowel obstruction have been reported since launch and are under study.

Two practical points. Slowed stomach emptying can affect how other pills absorb and matters before anesthesia; surgeons ask patients to pause it. And because the drug is meant to be taken indefinitely, decades-long safety data does not exist yet for anyone who started as an adult without diabetes.

Compounded and “research” semaglutide

Shortages and a list price of over $1,000 a month pushed people to compounding pharmacies and to research-chemical vendors. The FDA ended the shortage-based allowance for mass compounding and has warned about products that used a different salt form of the molecule, wrong doses, and unverified vials. A cheap vial labeled semaglutide has none of the trial evidence behind it, because nobody has verified what is in it. See the safety guide.

How it compares

• Tirzepatide adds a second gut-hormone receptor and produced about 21% weight loss in its main trial versus semaglutide’s 15%; it does not yet have a completed heart-outcomes trial.
• Tesamorelin targets deep belly fat through growth hormone; much smaller total effect, different mechanism.
• AOD-9604 is a growth hormone fragment whose human trial failed; not comparable.
• The fat loss guide and the GLP-1 guide cover the whole class.

Legal status

FDA approved: Ozempic (2017, diabetes), Wegovy (2021, weight management; 2024, heart risk reduction), Rybelsus (2019). Prescription only, approved in most countries. Not a controlled substance. Not on the WADA Prohibited List.

Bottom line

Semaglutide is what a peptide looks like when it goes all the way: large trials, a clear effect, a known list of side effects, and an approval. The weight comes back if you stop, a third of it is muscle on the way down, and the cheap versions are not the drug that was tested.

References

1. Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. PubMed
2. Marso SP, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. PubMed
3. Lincoff AM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. PubMed
4. Blundell J, et al. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. PubMed

See also

• Peptide
  AOD-9604: Research, Mechanism, and What the Evidence Actually Shows

  AOD-9604 is the tail end of the growth hormone molecule, kept for its fat-burning signal and stripped of everything else. Mice lost half their fat on it; a 300-person human trial missed its primary goal.

• Peptide
  Tesamorelin: The FDA-Approved GHRH Analog With Clinical Evidence for Visceral Fat Reduction

  Tesamorelin (Egrifta) is a lab-made version of GHRH, the signal that tells the pituitary to release growth hormone, and the only one with current FDA approval. In Phase III trials it cut deep belly fat by about 18% in people with HIV.

• Peptide
  Tirzepatide: What the Clinical Evidence Shows About This Dual Incretin Agonist

  Tirzepatide is a weekly injection that copies two gut hormones, GLP-1 and GIP. In its main trial, 2,539 adults lost an average of 20.9% of their body weight in 72 weeks, the largest loss any drug has produced, and it beat semaglutide head to head.